Investigational drug · Phase 2
Plixorafenib
Also called: FORE8394, PLX-8394
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer Harboring BRAF Alterations, HGG, LGG.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "Plixorafenib"
First trial start
2023
Feb 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Plixorafenib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer Harboring BRAF Alterations
- HGG
- LGG
- Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Plixorafenib" as an intervention, largest first.
Fore BiotherapeuticsIndustry
NCT05503797 · 254 participants (planned) · Start Feb 21, 2023 · Primary completion Dec 31, 2027
Drug: Plixorafenib · For: Cancer Harboring BRAF Alterations; HGG; LGG and 1 more
Sites: Beverly Hills, California; San Francisco, California; Westwood, Los Angeles, California · 70 sites in all
Fore BiotherapeuticsIndustry
NCT06385119 · 28 participants · Start Apr 24, 2024 · Primary completion Dec 22, 2024
Drug: Plixorafenib; Cobicistat · For: Healthy Participants
Sites: Austin, Texas
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT06610682 · 24 participants (planned) · Start Apr 7, 2025 · Primary completion Jun 30, 2027
Drug: Plixorafenib; Retifanlimab · For: BRAF V600E Mutation
Sites: Baltimore, Maryland; New York, New York
- Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot StudyNot yet recruiting
Olivia Newton-John Cancer Research InstituteAcademic, hospital or other
NCT07908147 · 12 participants (planned) · Start Mar 2027 · Primary completion Mar 2028
Drug: Larotrectinib; Cadonilimab and 1 more · For: IDH Wildtype Glioblastoma; Glioblastoma (GBM)
Sites: Heidelberg, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Computational and pharmacophore-based study of Camellia sinensis phytochemicals targeting BRAF in melanoma.
Shuvo MSP, Niaz SMR, Jannat S, et al. · Sci Rep 2025
- Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis.
Yi JS, McCarthy KS, Mazur K, et al. · JCO Precis Oncol 2025
- Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation.
Ohoka N, Suzuki M, Uchida T, et al. · Cancer Sci 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.